Evidence map›Paper›PMID 39261919›Full record

ArticleClinical epigenetics2024

Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype.

Johanna Thomas, Usama-Ur Rehman, Helena Bresser, Olga Grishina, Dietmar Pfeifer, Etienne Sollier, Konstanze Döhner, Christoph Plass, Heiko Becker, Claudia Schmoor and 2 more

Registry-linked trialAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00867672 (Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00867672 phase2completednot on this map

Prospective Randomized Multicenter Phase II Trial of Low-dose Decitabine (DAC) Administered Alone or in Combination With the Histone Deacetylase Inhibitor Valproic Acid (VPA) and All-trans Retinoic Acid (ATRA) in Patients > 60 Years With Acute Myeloid Leukemia Who Are Ineligible for Induction Chemotherapy

TypeinterventionalSponsorUniversity Hospital FreiburgRan2011 to 2016Enrolled204ConditionsAcute Myeloid LeukemiaArmsDecitabine, VPA, ATRA
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Johanna ThomasDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Usama-Ur RehmanDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Helena BresserDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Olga GrishinaFaculty of Medicine, University Medical Center Freiburg, Clinical Trials Unit, Freiburg, Germany.
Dietmar PfeiferDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Etienne SollierCancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Konstanze DöhnerDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Christoph PlassCancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Heiko BeckerDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany.
Claudia SchmoorFaculty of Medicine, University Medical Center Freiburg, Clinical Trials Unit, Freiburg, Germany.
Maike de WitDepartment of Hematology, Oncology and Palliative Medicine, Vivantes Klinikum Neukoelln, Berlin, Germany.
Michael LübbertDepartment of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, Hugstetterstr. 55, 79106, Freiburg, Germany. Michael.luebbert@uniklinik-freiburg.de.

Funding

Deutsche Forschungsgemeinschaft FOR2674 A02Deutsche Forschungsgemeinschaft FOR2674 A05Deutsche Forschungsgemeinschaft FOR2674 A09German Federal Ministry of Education and Research (BMBF, Clinical Trials Program) 01KG0913
6 · The paper itself

Abstract

DNA-hypomethylating agents (HMAs) induce notable remission rates in AML/MDS patients with TP53 mutations; however, secondary resistance often develops rapidly. In the DECIDER trial (NCT00867672), elderly AML patients (also those with adverse genetics) randomized to all-trans retinoic acid (ATRA) added to decitabine (DEC) attained significantly delayed time-to-resistance. An 82-year-old patient with a non-disruptive, in-frame TP53 mutation (p.Cys238_Asn239delinsTyr, VAF 90%) and complex-monosomal karyotype attained a complete hematologic and cytogenetic remission with DEC + ATRA, with 3.7 years survival after 30 treatment cycles that were well-tolerated. Further HMA + ATRA studies appear warranted in AML/MDS patients of different genetic risk groups ineligible for more intensive treatment.Trial registration: This trial was registered at ClinicalTrials.gov identifier: NCT00867672.

Indexed as

DecitabineLeukemia, Myeloid, AcuteRemission InductionTretinoinTumor Suppressor Protein p53Aged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsHumansKaryotypeMutationRandomized Controlled Trials as TopicDecitabineTP53 protein, humanTretinoinTumor Suppressor Protein p53

Identifiers

PMID39261919
PMCPMC11391765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.